Cambrex Expands Manufacturing Capacity at Swedish Drugs Facility
14th July 2020
Cambrex, a US-based manufacturer of active pharmaceutical ingredients (APIs), is investing $3.6 million to expand flexible drug substance manufacturing at its Swedish site in Karlskoga. Engineering has already begun, and work is expected to be completed by November 2020.
The project will lift capacity by 25% by converting a previously customer-dedicated manufacturing train by modifying an existing four-reactor configuration, adding another production line and installing new holding tanks as well as a Hastelloy Rosemund filter.
Bjarne Sandberg, Cambrex Karlskoga’s managing director, said: “We are seeing continued growth in commercial-scale API manufacturing, and an ongoing trend for customers favoring high-quality European and US partners, so we must ensure capacity is both flexible and available to be in a position to react quickly and effectively to customers’ changing requirements.”
The Karlskoga site, which employs over 400 people, houses a wide range of flexible manufacturing facilities, including four cGMP pilot plants and five full-scale commercial production units. Last year, Cambrex added a new process and analytical development facility along with a logistics center.
For more information visit www.chemanager-online.com/en